Pazopanib-induced chylothorax in a patient with renal cell carcinoma

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorKöylü, Bahadır
dc.contributor.authorTekin, Fatih
dc.contributor.authorAktaş, Burak Yasin
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorKöksal, Deniz
dc.date.accessioned2021-08-19T06:39:42Z
dc.date.available2021-08-19T06:39:42Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPazopanib is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC). It is an anti-angiogenic agent, which blocks the activation signaling pathways of tyrosine kinases and prevents the activities of primarily vascular endothelial growth factor receptors (VEGFR)-2 and VEGFR-3, which are important in lymphangiogenesis. Herein, we report a patient with advanced RCC who developed asymptomatic left-sided chylothorax under pazopanib therapy. Chylothorax developed in the 16th month and gradually increased until it was diagnosed by thoracentesis in the 22nd month. The development of chylothorax was attributed to pazopanib therapy after ruling out all possible traumatic and nontraumatic etiologies. The 'Adverse Drug Reaction Probability Scale' revealed a total score of 6, which fell into 'probable' category. Chylothorax regressed significantly 5 weeks after the discontinuation of pazopanib therapy.en_US
dc.identifier.citationKoylu, B., Tekin, F., Aktas, B. Y., Kilickap, S., & Koksal, D. (2021). Pazopanib-induced chylothorax in a patient with renal cell carcinoma. Anti-cancer drugs, 10.1097/CAD.0000000000001172. Advance online publication. https://doi.org/10.1097/CAD.0000000000001172en_US
dc.identifier.doi10.1097/CAD.0000000000001172en_US
dc.identifier.endpage3en_US
dc.identifier.pmid34387587en_US
dc.identifier.scopus2-s2.0-85122714407en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001172
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2005
dc.identifier.wosWOS:000780317000072en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherWolters Kluweren_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePazopanib-induced chylothorax in a patient with renal cell carcinomaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
87.pdf
Boyut:
488.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu